FyMed, Inc.

Press Releases

FyMed Announces Notice of Allowance for US Patent Covering Fy10 Technology Platform

FyMed Inc., a specialty pharmaceutical company focused on the development and commercialization of novel therapeutics announced that its application covering the Fy10 technology platform was allowed for issuance as a new patent by the USPTO.
Wilmington, DE

FyMed Inc., a specialty pharmaceutical company focused on the development and commercialization of novel therapeutics announced that its application covering the Fy10 technology platform was allowed for issuance as a new patent by the USPTO. The patent contains claims that cover broad coverage of immunomodulatory and anti-inflammatory drugs using Fy10 technologies that can be used in the treatment of autoimmune diseases.

“These newly allowed claims further strengthen our intellectual property portfolio covering the Fy10 technology platform", the Company said. FY103B, FyMed's lead NSAID candidate identified using the Fy10 technology demonstrated superior therapeutic effects in the management of acute and chronic pain and inflammation, and was found to be significantly superior to celecoxib in terms of efficacy and safety. FY103B was further developed through extensive mechanism of action studies that integrates advanced pharmacogenomics and proteomics, and was also found to exhibit significant reductions in the risk of developing oesophageal, stomach, and intestinal cancers.

FyMed applies integrated molecular phenotypic based innovative approaches in studies with companion prognostic driven drug-centric modalities.

About FyMed

FyMed, Inc. is a pharmaceutical company with a growing portfolio of novel and improved pharmaceuticals developed and enhanced through targeted use of next-generation proteomic and genomic technologies in drug discovery and development. Leading innovations in precision medicine has enabled FyMed to effectively balance technological innovation with scientific discovery, creating tools that can productively capitalize on key market deficiencies.

Safe Harbor Statement

To the extent any statements made in this document contain information that is not historical, this news release contains "forward-looking statements" within the meaning of Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of the words "intends," "plans," "will," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described herein. These risks and uncertainties may include, without limitation, projected expansions, outcomes of our clinical trials, achievement of our business objectives, and the ability to obtain necessary regulatory approvals. FyMed undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise.

Contact:
Media Relations, FyMed, Inc.
3422 Old Capitol, Suite 1610
Wilmington, DE 19808
Tel: 302-722-5010
Email: media@fymed.com
http://www.fymed.com/media.html